The fact sheets, updated March 18, outline how certain variants may affect efficacy of the three antibody therapies with emergency use approval in the U.S.
Variants discussed in the fact sheets are:
- B.1.1.7 (U.K. origin)
- B.1.351 (South Africa origin)
- P.1 (Brazil origin)
- B.1.427/B.1.429 (California origin)
- B.1.526 (New York origin)
“Some variants can cause resistance to one or more of the mAb therapies authorized to treat COVID-19,” the FDA said. “Healthcare providers should consider the prevalence of mAb-resistant variants in their area, where data are available, when considering treatment options.”
To learn more, click here.
More articles on patient safety and outcomes:
NYC Health + Hospitals aims to reduce unneccessary care with new guidelines
COVID-19 death risk 64% higher for UK variant, study suggests
10 top patient safety concerns for 2021, ranked by ECRI Institute
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
